Glucotrack and Lōkahi Therapeutics Close Merger to Form AI-Driven Public Biotech

Glucotrack and Lōkahi Therapeutics finalized a strategic business combination that hands Lōkahi Therapeutics controlling interest in a newly structured public company, the firms announced via GlobalNewswire. The deal gives the combined entity direct access to public capital markets while folding in Lōkahi's proprietary ai²-driven platform for sourcing, developing, and advancing therapeutic assets.

The merger is designed around capital efficiency, allowing the combined company to repeatedly identify and develop drug candidates without the overhead traditionally associated with building a large internal pipeline from scratch. Lōkahi's ai² platform sits at the core of that strategy, applying artificial intelligence to streamline asset selection and development decision-making — a model that executives say is both scalable and repeatable.

Read more BlackRock's GIP to Acquire Majority Stake in Summit Ridge Energy →

The transaction reflects a broader trend in biotechnology where smaller firms use reverse-merger or business-combination structures to gain public-market footing quickly, sidestepping the cost and time demands of a traditional IPO. By pairing Glucotrack's existing public listing with Lōkahi's technology platform, the combined company aims to punch above its weight class in a competitive drug-development landscape.

While specific pipeline assets and financial terms were not disclosed in the announcement, the strategic logic centers on using public equity as a flexible funding mechanism to fuel Lōkahi's AI-guided development engine. Investors and industry observers will be watching closely to see how the combined company translates its technology-forward thesis into clinical and commercial milestones.

Continue reading at GlobalNewswire.